Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Samsca Tops January “Mind Share” Ranking in HP Market
March 5, 2014
- Eylea Filed for Diabetic Macular Edema in Japan: Bayer HealthCare
March 5, 2014
- Takeda Extended 3.7 Billion Yen in CASE-J-Linked Grants to Kyoto Univ., 2 Entities; “No COI” Says Pres. Hasegawa
March 4, 2014
- Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
- DSP Transfers Marketing Rights for Inteban, Catlep, and Drenison to Teikoku Seiyaku
March 4, 2014
- Astellas Secures Exclusive Rights for Isavuconazole in US, Canada
March 4, 2014
- Dnavec, NCGM, Nippon Zenyaku to Codevelop Drug Discovery Tool for Anti-Obesity Treatment
March 3, 2014
- Takeda Files NDA for Promising Acid-Related Disease Drug in Japan
March 3, 2014
- Novartis Files for Approval of Exforge OD Tablets
March 3, 2014
- Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
- Mizuho Projects 5% Upswing for FY2014 Operating Profit of 9 Major Japan Pharmas
February 28, 2014
- Nipro Opens Sales Subsidiary in Sweden
February 28, 2014
- Fujifilm Sets Up Chinese Subsidiary for Regenerative Medicine Business, Eyeing Provision of Epidermis Culturing Services by 2015
February 28, 2014
- All DPP-4 Inhibitors to Undergo Major Price Reductions Due to Market Expansion of Januvia/Glactiv; Re-pricing Could Affect SGLT-2 Inhibitors as Well
February 28, 2014
- 72 Drug Makers Provided 483 Billion Yen in Funding to Medical and Research Institutions in FY2012
February 27, 2014
- Quintiles to Increase Contract Sales Reps in Japan: Global Commercial Head Evangelista
February 26, 2014
- Shionogi Announces Reorganization to Boost R&D Capabilities
February 26, 2014
- Ranbaxy’s Toansa, Dewas Plants Voluntarily Suspend API Shipments Worldwide
February 26, 2014
- Takeda to Realign Japan Sales Team
February 25, 2014
- Ajinomoto Aims to Increase Operating Profit Rate to 10% in Pharmaceuticals Segment in FY2016 Under New Midterm Plan
February 24, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…